Challenges in estimating the counterfactual placebo HIV incidence rate from a registration cohort: The PrEPVacc trial.

导出 LinkOut

翻译打印收藏纠错

作者： Sheila,Kansiime ^[1] ; Christian Holm,Hansen ^[2] ; Eugene,Ruzagira ^[3] ; Sheena,McCormack ^[4] ; Richard,Hayes ^[2] ; David,Dunn ^[4]

作者单位： Medical Research Council/Uganda Virus Research Institute and The London School of Hygiene & Tropical Medicine, Uganda Research Unit, Entebbe, Uganda.;Medical Research Council International Statistics and Epidemiology Group, The London School of Hygiene & Tropical Medicine, London, UK. ^[1] Medical Research Council International Statistics and Epidemiology Group, The London School of Hygiene & Tropical Medicine, London, UK. ^[2] Medical Research Council/Uganda Virus Research Institute and The London School of Hygiene & Tropical Medicine, Uganda Research Unit, Entebbe, Uganda. ^[3] Medical Research Council Clinical Trials Unit, University College London, London, UK. ^[4]

关键词 HIV active-controlled trials counterfactual placebo HIV incidence novel HIV trial designs pre-exposure prophylaxis sub-Saharan Africa

DOI 10.1177/17407745241304721

PMID 39847674

发布时间 2025-02-12

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览0

Clinical trials (London, England)

17407745241304721页

相似文献

中文期刊
外文期刊
学位论文
会议论文

检索历史清除

Challenges in estimating the counterfactual placebo HIV incidence rate from a registration cohort: The PrEPVacc trial.

Clinical trials (London, England)

相似文献

Clinical trials (London, England)

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

Challenges in estimating the counterfactual placebo HIV incidence rate from a registration cohort: The PrEPVacc trial.

Clinical trials (London, England)

相似文献

Clinical trials (London, England)

相关期刊

检索历史清除